GR1803

Phase 2Small molecule

GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

GR1803 is one of 88 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusRecruiting

Multiple MyelomaRecruiting

Systemic Lupus ErythematosusPhase 2

Recruiting

Multiple MyelomaPhase 2

Recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

TALVEY

Johnson & Johnson

Phase 3

24 3

Venclexta

AbbVie

Phase 3

17 4

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 5

Biaxin

AbbVie

Phase 3

15 6

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 7

Neulasta

Amgen

Phase 3

5 8

Vepesid

AAvyxa

Phase 3

17 9

Busulfex

Akero Therapeutics

Phase 3

15 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Multiple Myeloma

NCT06566547

Q4 2027

Phase 1/2Recruiting

Systemic Lupus Erythematosus

NCT07348055

Phase 2Recruiting

Study completion

NCT06952075

Q1 2030

Phase 1/2Not yet recruiting

Multiple Myeloma

NCT07090954

Phase 3Recruiting

Multiple Myeloma

NCT07452198

Clinical

Trials by Indication[1]

Multiple Myeloma3 trials

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 3·NCT07452198·358 enrolled

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06566547·116 enrolled

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Not yet recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 1/2·NCT07090954·32 enrolled

Trial1 trial

Phase I Trial of GR1803 Injection in Patients With RRMM

Completed·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 1/2·NCT07102706·76 enrolled

Systemic Lupus Erythematosus1 trial

A Study of GR1803 in Systemic Lupus Erythematosus

Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 1/2·NCT07348055·44 enrolled

Unspecified1 trial

GR1803 Injection in Patients With RRMM

Recruiting·GGenrix (Shanghai) Biopharmaceutical Co., Ltd.·Phase 2·NCT06952075·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for GR1803. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GR1803 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GR1803. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genrix (Shanghai) Biopharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGenrix (Shanghai) Biopharmaceutical Co., Ltd.

GR1803

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2030

Trials by Indication[1]

Multiple Myeloma3 trials

Trial1 trial

Systemic Lupus Erythematosus1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News